Education
About Us
Working with TipRanks
Follow Us
Elicio Therapeutics (ELTX)
NASDAQ:ELTX
ELTX Stock Chart & Stats
$8.88
$0.10(1.66%)
At close: 4:00 PM EST
$8.88
$0.10(1.66%)
Day’s Range― - ―
52-Week Range$4.60 - $14.93
Previous CloseN/A
Volume37.28K
Average Volume (3M)77.23K
Market Cap
$206.73M
Enterprise Value$188.72M
Total Cash (Recent Filing)$20.61M
Total Debt (Recent Filing)$5.34M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Mar 27, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding17,489,515
10 Day Avg. Volume85,490
30 Day Avg. Volume77,231
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-5.50
Price to Sales (P/S)0.00
P/FCF Ratio-1.68
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-217.93
Enterprise Value/Ebitda-4.32
Forecast
1Y Price Target
$18.00Price Target Upside102.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.51
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biological Activity And Immune ResponseManagement reported ELI-002 induced KRAS-specific T cell responses in nearly all evaluable pancreatic cancer patients in the Phase 2 trial, providing a strong biological signal that supports the vaccine approach.
Regulatory Pathway ClarificationPositive interim Phase 2 data would prompt management to seek an End-of-Phase 2 meeting with the FDA to finalize a pivotal Phase 3 design, creating a clearer regulatory path forward.
Trial Design And Statistical PowerAnalyst notes the randomized Phase 2 trial is designed with sufficient statistical power and enrolls both measurable residual disease–positive and –negative patients in subgroup sizes that allow meaningful statistical comparisons, increasing the chance of a definitive efficacy readout.
Bears Say
Cash Runway PressureCompany's limited cash relative to ongoing development needs implies additional financing may be required before the next major clinical milestone, which could pressure valuation.
Data Readout Uncertainty And Stock VolatilityPostponed data readout because the trial has not reached the required event count prolongs uncertainty about efficacy and can sustain short-term stock volatility.
Financing Need And Dilution RiskManagement plans to raise capital to initiate a pivotal Phase 3 trial, creating potential dilution and execution risk if Phase 2 results are not favorable.
Elicio Therapeutics News
ELTX FAQ
What was Elicio Therapeutics’s price range in the past 12 months?
Elicio Therapeutics lowest stock price was $4.60 and its highest was $14.93 in the past 12 months.
What is Elicio Therapeutics’s market cap?
Elicio Therapeutics’s market cap is $206.73M.
When is Elicio Therapeutics’s upcoming earnings report date?
Elicio Therapeutics’s upcoming earnings report date is Mar 27, 2026 which is in 20 days.
How were Elicio Therapeutics’s earnings last quarter?
Elicio Therapeutics released its earnings results on Nov 13, 2025. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.48 by -$0.12.
Is Elicio Therapeutics overvalued?
According to Wall Street analysts Elicio Therapeutics’s price is currently Undervalued.
Does Elicio Therapeutics pay dividends?
Elicio Therapeutics does not currently pay dividends.
What is Elicio Therapeutics’s EPS estimate?
Elicio Therapeutics’s EPS estimate is -0.45.
How many shares outstanding does Elicio Therapeutics have?
Elicio Therapeutics has 17,489,515 shares outstanding.
What happened to Elicio Therapeutics’s price movement after its last earnings report?
Elicio Therapeutics reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.48. Following the earnings report the stock price went down -0.871%.
Which hedge fund is a major shareholder of Elicio Therapeutics?
Currently, no hedge funds are holding shares in ELTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elicio Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (102.70% Upside)
$18.00 (102.70% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
96.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
87.48%
Trailing 12-Months
Company Description
Elicio Therapeutics
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
ELTX Stock 12 Month Forecast
Average Price Target
$18.00
▲(102.70% Upside)
Technical Analysis
Compugen
―
Cassava Sciences
―
Seres Therapeutics
―
Milestone Pharmaceuticals
―
Actuate Therapeutics, Inc.
―
Ownership Overview
33.33% Insiders
2.96% Mutual Funds
0.53% Other Institutional Investors
60.68% Public Companies and
Individual Investors